Clinical trial
A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Treatment on Plaque Burden as Determined by Intravascular Ultrasound and to Evaluate the Efficacy, Pharmacokinetics, Safety, and Tolerability of MDCO-216 Given as Multiple Weekly Infusions in Subjects With a Recent Acute Coronary Syndrome
NCT02678923 is registered in ClinicalTrials.gov with The Medicines Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Treatment on Plaque Burden as Determined by Intravascular Ultrasound and to Evaluate the Efficacy, Pharmacokinetics, Safety, and Tolerability of MDCO-216 Given as Multiple Weekly Infusions in Subjects With a Recent Acute Coronary Syndrome
- Lead sponsor
- The Medicines Company
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 3, 2015
- Completion date
- October 26, 2016
- Enrollment
- 126 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.